Results 241 to 250 of about 16,747 (255)

Anidulafungin: an echinocandin antifungal

Expert Opinion on Investigational Drugs, 2004
Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
openaire   +2 more sources

Molecular Detection of Resistance to Echinocandins

2016
In the last years, life-threatening fungal diseases have increased significantly, due to the rising number of human individuals susceptible to fungal infections, which are in part complicated by the emergence of antifungal drug-resistant pathogens.
Posteraro, Brunella, Vella, Antonietta, De Carolis, Elena, Sanguinetti, Maurizio   +3 more
openaire   +3 more sources

Echinocandins: The Expanding Antifungal Armamentarium

Clinical Infectious Diseases, 2015
The echinocandins are large lipopeptide molecules that, since their discovery approximately 41 years ago, have emerged as important additions to the expanding armamentarium against invasive fungal diseases. Echinocandins exert in vitro and in vivo fungicidal action against most Candida species and fungistatic action against Aspergillus species. However,
Daniel Aguilar-Zapata, Vidmantas Petraitis, Ruta Petraitiene   +2 more
openaire   +3 more sources

Echinocandin-Resistenzen in \(Candida\) \(glabrata\)

2022
Candida glabrata ist die zweithäufigste Ursache von Candidämien und invasiven Hefepilzinfektionen in Europa. Im Gegensatz zu C. albicans zeigt C. glabrata eine reduzierte Empfindlichkeit gegen bestimmte Antimykotika und kann unter Therapie rasch Resistenzen entwickeln.
openaire   +1 more source

Clinical efficacy of echinocandin antifungals

Current Opinion in Infectious Diseases, 2001
The prevalence of fungal infections has increased significantly over the past few decades. Candida and Aspergillus spp. are the most common fungal pathogens due to recent changes in medical technology. Amphotericin B continues to be the treatment of choice in many severe disseminated mycosis cases, but problems with toxicity, resistance and non ...
openaire   +3 more sources

Echinocandins in invasive candidiasis

Mycoses, 2013
SummaryWe summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managingIC. The echinocandins have demonstrated good activity against non‐albicansinfections and also azole‐resistant strains, both preclinically and in recent clinical trials.
George Dimopoulos, Siriporn Wittayachanyapong, B. Shoib Mohd Sany, Melor Mansor, Hoe Nam Leong, Marie Yvette C. Barez, Sheng-Fong Lin, Hsin-Yun Sun, Atul Patel, Bambang Wahjuprajitno, John Simon, Deepak Talwar, Po-Yen Huang, Jen-Hsien Wang   +13 more
openaire   +2 more sources

Echinocandin antifungals: review and update

Expert Review of Anti-infective Therapy, 2006
The echinocandins are a new and unique class of antifungal agents that act on the fungal cell wall by way of noncompetitive inhibition of the synthesis of 1,3-beta-glucans. All agents of this class are of parenteral formulation, with no oral preparations available.
openaire   +3 more sources

Caspofungin: An echinocandin antifungal agent

Clinical Therapeutics, 2002
The mainstays of treatment for nosocomial fungal infections have been amphotericin B and azole derivatives. Caspofungin acetate is a new echinocandin antifungal agent with a mechanism of action that targets a structural component of the fungal cell wall.This article describes the pharmacologic properties and potential clinical usefulness of caspofungin.
Horatio B. Fung, Elizabeth A. Stone, Harold L. Kirschenbaum   +2 more
openaire   +3 more sources

Micafungin: A New Echinocandin Antifungal

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
The echinocandins represent the newest class of antifungals to combat infections caused by Candida sp. Micafungin is an echinocandin recently approved by the United States Food and Drug Administration. It is indicated in adults for esophageal candidiasis and prophylaxis against candidal infections in hematopoietic stem cell transplant recipients ...
Jomy M. Joseph, Larry H. Danziger, Rupali Jain   +2 more
openaire   +3 more sources

Echinocandins in the Treatment of Aspergillosis

2014
In the presence of caspofungin, blunting and abnormal branching of the hyphae in actively growing areas of the cell are observed, primarily at the tips and branching points. These observations are consistent with the mechanism of action but do not fit the classical definitions of a fungicidal or fungistatic agent. Echinocandins are large molecules with
Vincent Maertens, Johan Maertens
openaire   +2 more sources